ESMO 2025 – Novartis looks for Pluvicto prostate Addition
But the ESMO discussant recommends against widespread use in hormone-sensitive disease.
ESMO 2025 preview – a bemarituzumab reckoning approaches
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
J&J goes straight into phase 3 in prostate
The company is to test its KLK2-targeting pasritamig in a late-line setting.
ASCO 2025 – J&J takes another prostate cancer shot
The company highlights the safety of its KLK2-targeting T-cell engager pasritamig.
